Indeed, several studies have shown that the presence of TILs and the expression of immune-associated gene signatures in pre-treatment biopsies are associated with longer DFS in HER2+ BC patients treated with anti-HER2-based therapy in the neoadjuvant or adjuvant settings (50). This evidence concerns the gene ERBB2 and breast cancer.